Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
For more information, contact our Adult Leukemia Program.
For more information, contact our Adult Lymphoma Program.
For more information, contact our Multiple Myeloma Program.
For more information, contact the relevant solid tumor treatment center.
Glenn Hanna, MD, describes the trial of CTLA-4 inhibition in combination with memory-like natural killer (NK) cell immune cell therapy in advanced head and neck cancer.
For some cellular therapy products – especially in early phase clinical trials – our on-site Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) performs the primary cell manufacturing of genetically engineered products. For other cellular therapy products, cells are primarily manufactured at an outside commercial facility and the CMCF oversees the process of collecting the cells, shipment to the offsite commercial facility, return of the processed cells, and release for patient treatment.
New Patient Appointments